4 Reasons To Buy AbbVie

An analyst maintains a 'Buy' rating on AbbVie (ABBV), emphasizing its medium-to-long-term potential despite recent outlook downgrades and short-term tariff risks. The investment thesis is underpinned by the assessment that recent guidance cuts are minor, with earnings growth anticipated by Q2 2025, and the company's attractive dividend yield. Furthermore, AbbVie's strategic expansion of US manufacturing is expected to mitigate long-term tariff pressures. The analyst also disclosed an intent to potentially initiate a long position in ABBV within the next 72 hours.

Analysis

The investment thesis for AbbVie (ABBV) is presented with a medium-to-long-term bullish outlook, underpinned by a "Buy" rating that discounts recent headwinds. The analysis acknowledges recent outlook downgrades but frames them as minor and insufficient to derail the core investment case. Key positive drivers identified are the company's attractive dividend, providing yield in an uncertain environment, and a specific forecast for a return to earnings growth in Q2 2025. While short-term margin pressure from tariff risks is noted as a headwind, the company's strategic plan to expand US-based manufacturing is presented as a significant long-term mitigator. The analyst's stated intent to potentially initiate a long position within 72 hours reinforces the strong conviction behind this positive assessment.

Key Decisions for Investors

• Investors with a long-term horizon could view the current situation as a buying opportunity, focusing on the expected earnings rebound in Q2 2025 and the supportive dividend yield.
• It is prudent to monitor the near-term impact of tariff policies on AbbVie's margins and any further revisions to corporate guidance, as these are the primary short-term risks.
• Progress on AbbVie's planned expansion of its US manufacturing footprint should be tracked as a key indicator of its ability to de-risk its long-term supply chain and margin profile.